Latest Drug Safety Monitoring News

Page 1 of 1

Dimerix’s DMX-200 Trial Clears Sixth Safety Review, Advancing Hope for FSGS Patients

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in treating FSGS kidney disease has passed its sixth independent safety review with no concerns, reinforcing the drug’s promising safety profile.

Ada Torres

22 May 2025

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026